RNA Aptamer-Based Screen for Selective Inhibitors of GRK2

基于 RNA 适体的 GRK2 选择性抑制剂筛选

基本信息

  • 批准号:
    7929294
  • 负责人:
  • 金额:
    $ 3.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-01 至 2012-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A small family of G protein-coupled receptor (GPCR) kinases (GRKs) negatively regulates heterotrimeric G protein signaling by phosphorylating multiple sites in the cytoplasmic loops and tails of activated GPCRs. Through this process, cells adapt to persistent stimuli that act at GPCRs and protect themselves from damage incurred by sustained signaling. GRKs can also play maladaptive roles in human disease. GRK2 is overexpressed during heart failure, which not only uncouples cardiac receptors from the central nervous system, but also promotes the release of excessive amounts of catecholamines from the adrenal gland. Inhibition of GRK2 by transgenic peptides prevents cardiac failure in mouse models, suggesting that GRK2 is an excellent target for the treatment of heart disease. However, selective small molecule inhibitors of GRKs have not been reported, perhaps due to high homology among the active sites of GRKs and other AGC kinases. Over the last six years, our lab has made significant progress in understanding the structure and function of GRKs, and we are currently investigating the molecular basis for the selective inhibition of GRK2 by a high affinity RNA aptamer. Our preliminary crystallographic studies of this complex demonstrate that the aptamer binds primarily to the large lobe of the kinase domain, where it blocks the entrance to the nucleotide binding site of the kinase domain. We hypothesize that this RNA aptamer can be used in a displacement assay to identify small molecules that bind to regions on GRK2 outside of its active site that are also critical for activity. We have designed improved versions of the original RNA aptamer for use in a robust flow cytometry protein interaction assay to screen for compounds that compete with RNA binding to GRK2. In collaboration with the Center for Chemical Genomics at the University of Michigan, we have conducted a preliminary HTS of ~40,000 compounds with excellent statistics. Using activity-based secondary screens, we will confirm which hits derived from this screen and those from screens conducted at a Molecular Libraries Probe Production Center bind directly to GRK2 and inhibit kinase activity. These compounds will be further characterized to establish membrane permeability, their mode of inhibition, and their selectivity for GRK2. Although all active molecules are of interest, small molecules that do not exhibit competitive inhibition with ATP are of particular importance because they would likely represent novel and selective therapeutic leads for the treatment of heart disease. PUBLIC HEALTH RELEVANCE: GRK2 is strongly linked to cardiovascular physiology and disease. Our flow cytometry protein interaction assay will allow us to rapidly screen large libraries of small molecules with the goal of identifying compounds that interfere with a high-affinity RNA aptamer that selectively binds to the kinase domain of GRK2. These compounds have the potential to interact with novel sites on the surface of the kinase domain and thus serve as selective inhibitors of GRK2.
描述(由申请人提供):G蛋白偶联受体(GPCR)激酶(GRKs)的一个小家族通过磷酸化激活GPCR的胞质环和尾部中的多个位点来负调节异源三聚体G蛋白信号传导。通过这一过程,细胞适应作用于GPCR的持续刺激,并保护自己免受持续信号传导造成的损害。GRKs也可以在人类疾病中发挥适应不良的作用。GRK2在心力衰竭期间过表达,这不仅使心脏受体与中枢神经系统解偶联,而且还促进肾上腺释放过量的儿茶酚胺。通过转基因肽抑制GRK2可以预防小鼠模型中的心力衰竭,这表明GRK2是治疗心脏病的极好靶点。然而,选择性小分子抑制剂的GRKs尚未报道,可能是由于高同源性的活性位点的GRKs和其他AGC激酶。在过去的六年中,我们的实验室在理解GRKs的结构和功能方面取得了重大进展,我们目前正在研究高亲和力RNA适体选择性抑制GRK2的分子基础。我们对该复合物的初步晶体学研究表明,适体主要与激酶结构域的大叶结合,在那里它阻断了激酶结构域的核苷酸结合位点的入口。我们假设这种RNA适体可以用于置换试验,以识别与GRK 2活性位点之外的区域结合的小分子,这些区域对于活性也至关重要。我们已经设计了原始RNA适体的改进版本,用于稳健的流式细胞术蛋白质相互作用测定,以筛选与RNA竞争结合GRK2的化合物。与密歇根大学化学基因组学中心合作,我们已经对约40,000种化合物进行了初步的HTS,并获得了出色的统计数据。使用基于活性的二次筛选,我们将确认来自该筛选的命中和来自在分子文库探针生产中心进行的筛选的命中直接结合GRK2并抑制激酶活性。将进一步表征这些化合物以确定膜渗透性、它们的抑制模式和它们对GRK2的选择性。尽管所有的活性分子都是感兴趣的,但不表现出与ATP竞争性抑制的小分子是特别重要的,因为它们可能代表用于治疗心脏病的新型和选择性治疗先导物。 公共卫生相关性:GRK2与心血管生理学和疾病密切相关。我们的流式细胞术蛋白质相互作用测定将使我们能够快速筛选大的小分子文库,目的是鉴定干扰选择性结合GRK2激酶结构域的高亲和力RNA适体的化合物。这些化合物具有与激酶结构域表面上的新位点相互作用的潜力,因此可作为GRK2的选择性抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Tesmer其他文献

John Tesmer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Tesmer', 18)}}的其他基金

New X-ray Diffractometer and Detector for Purdue Macromolecular Crystallography
用于普渡大学高分子晶体学的新型 X 射线衍射仪和探测器
  • 批准号:
    10431439
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
GPCR - Linked RhoGEFs in Tumor Growth and Metastasis
GPCR - 连接 RhoGEF 在肿瘤生长和转移中的作用
  • 批准号:
    10338123
  • 财政年份:
    2018
  • 资助金额:
    $ 3.86万
  • 项目类别:
FASEB SRC on G Protein-Coupled Receptor Kinases and Arrestins: From Structure to Disease
FASEB SRC 关于 G 蛋白偶联受体激酶和抑制蛋白:从结构到疾病
  • 批准号:
    9330648
  • 财政年份:
    2017
  • 资助金额:
    $ 3.86万
  • 项目类别:
Structure and Function of the LPLA2/LCAT Acyltransferase Family
LPLA2/LCAT 酰基转移酶家族的结构和功能
  • 批准号:
    9174909
  • 财政年份:
    2014
  • 资助金额:
    $ 3.86万
  • 项目类别:
Structure and Function of the LPLA2/LCAT Acyltransferase Family
LPLA2/LCAT 酰基转移酶家族的结构和功能
  • 批准号:
    8817382
  • 财政年份:
    2014
  • 资助金额:
    $ 3.86万
  • 项目类别:
RNA Aptamer-Based Screen for Selective Inhibitors of GRK2
基于 RNA 适体的 GRK2 选择性抑制剂筛选
  • 批准号:
    8063896
  • 财政年份:
    2010
  • 资助金额:
    $ 3.86万
  • 项目类别:
Molecular basis for the regulation of G protein-coupled receptor kinases
G蛋白偶联受体激酶调节的分子基础
  • 批准号:
    8281593
  • 财政年份:
    2009
  • 资助金额:
    $ 3.86万
  • 项目类别:
Molecular basis for the regulation of G protein-coupled receptor kinases
G蛋白偶联受体激酶调节的分子基础
  • 批准号:
    7906035
  • 财政年份:
    2009
  • 资助金额:
    $ 3.86万
  • 项目类别:
Phosphorylation and G Protein Signaling Networks Gordon Conferences
磷酸化和 G 蛋白信号转导网络 Gordon Conferences
  • 批准号:
    8076873
  • 财政年份:
    2009
  • 资助金额:
    $ 3.86万
  • 项目类别:
Molecular basis for the regulation of G protein-coupled receptor kinases
G蛋白偶联受体激酶调节的分子基础
  • 批准号:
    7736619
  • 财政年份:
    2009
  • 资助金额:
    $ 3.86万
  • 项目类别:

相似海外基金

NSF-BSF: Towards a Molecular Understanding of Dynamic Active Sites in Advanced Alkaline Water Oxidation Catalysts
NSF-BSF:高级碱性水氧化催化剂动态活性位点的分子理解
  • 批准号:
    2400195
  • 财政年份:
    2024
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334970
  • 财政年份:
    2024
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Standard Grant
Collaborative Research: Beyond the Single-Atom Paradigm: A Priori Design of Dual-Atom Alloy Active Sites for Efficient and Selective Chemical Conversions
合作研究:超越单原子范式:双原子合金活性位点的先验设计,用于高效和选择性化学转化
  • 批准号:
    2334969
  • 财政年份:
    2024
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Standard Grant
Mechanochemical synthesis of nanocarbon and design of active sites for oxygen reducton/evolution reactions
纳米碳的机械化学合成和氧还原/演化反应活性位点的设计
  • 批准号:
    23K04919
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Creation of porous inorganic frameworks with controlled structure of metal active sites by the building block method.
通过积木法创建具有金属活性位点受控结构的多孔无机框架。
  • 批准号:
    22KJ2957
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Catalysis of Juxaposed Active Sites Created in Nanospaces and Their Applications
纳米空间中并置活性位点的催化及其应用
  • 批准号:
    23K04494
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of carbon active sites by modifying the oxygen containing functional groups and structures of carbons for utilizing to various catalytic reactions.
通过修饰碳的含氧官能团和结构来产生碳活性位点,用于各种催化反应。
  • 批准号:
    23K13831
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CAREER: CAS: Understanding the Chemistry of Palladium and Silyl Compounds to Design Catalyst Active Sites
职业:CAS:了解钯和甲硅烷基化合物的化学性质以设计催化剂活性位点
  • 批准号:
    2238379
  • 财政年份:
    2023
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Continuing Grant
CAS: Collaborative Research: Tailoring the Distribution of Transient vs. Dynamic Active Sites in Solid-Acid Catalysts and Their Impacts on Chemical Conversions
CAS:合作研究:定制固体酸催化剂中瞬时活性位点与动态活性位点的分布及其对化学转化的影响
  • 批准号:
    2154399
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Standard Grant
Engineering of Active Sites in Heterogeneous Catalysts for Sustainable Chemical and Fuel Production.
用于可持续化学和燃料生产的多相催化剂活性位点工程。
  • 批准号:
    RGPIN-2019-06633
  • 财政年份:
    2022
  • 资助金额:
    $ 3.86万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了